FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
FDA Approves Merck’s NUMELVI for Allergic Dermatitis in Dogs
Merck Animal Health has received FDA approval for NUMELVI™ (atinvicitinib), a next-generation…
Rigel Pharmaceuticals Signs Global Licensing Deal for VEPPANU™ Breast Cancer Treatment
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and…
Rejoni Appoints Women’s Health MedTech Leader John Nealon as Chief Executive Officer
Rejoni Inc. has appointed John Nealon as Chief Executive Officer. With over…
Novo Nordisk Secures FDA Approval for Once-Weekly Basal Insulin Awiqli®
Novo Nordisk’s once-weekly insulin Awiqli® has received FDA approval after phase 3…
Abu Dhabi Fast-Tracks Innovative IBD Treatment with Johnson & Johnson and SSMC
On the side-lines of Abu Dhabi’s participation at BIO International Convention in…
FDA Approves Updated Label for GE Healthcare’s Vizamyl to Enhance Alzheimer’s Diagnosis and Therapy Monitoring
GE HealthCare announced that the U.S. Food and Drug Administration (FDA) has…
Datroway: A Novel TROP2‑Directed Therapy Approved for Lung Cancer
AstraZeneca and Daiichi Sankyo’s new antibody drug conjugate, Datroway (datopotamab deruxtecan), has received accelerated…
Yeztugo by Gilead Gets FDA OK, Promises Easier HIV Prevention
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA)…
New Abbott Heart Valve Offers Hope to Patients Who Can’t Undergo Open-Heart Surgery
For many heart patients living with severe mitral valve disease, open-heart surgery…
